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ABSTRACT
Objectives: The health effects of internal
contamination by radionuclides, and notably by
uranium, are poorly characterised. New cohorts of
uranium workers are needed to better examine these
effects. This paper analyses for the first time the
mortality profile of the French cohort of uranium cycle
workers. It considers mortality from cancer and
non-cancer causes.
Methods: The cohort includes workers employed at
least 6 months between 1958 and 2006 in French
companies involved in the production of nuclear fuel.
Vital status and causes of death were collected from
French national registries. Workers were followed-up
from 1 January 1968 to 31 December 2008.
Standardised mortality ratios (SMRs) were computed
based on mortality rates for the French general
population.
Results: The cohort includes 12 649 workers (88%
men). The average length of follow-up is 27 years and
the mean age at the end of the study is 60 years. Large
mortality deficits are observed for non-cancer causes
of death such as non-cancer respiratory diseases
(SMR=0.51 (0.41 to 0.63)) and circulatory diseases
(SMR=0.68 (0.62 to 0.74)). A mortality deficit of lower
magnitude is also observed for all cancers combined
(SMR (95% CI): 0.76 (0.71 to 0.81)). Pleural
mesothelioma is elevated (SMR=2.04 (1.19 to 3.27)).
Conclusions: A healthy worker effect is observed in
this new cohort of workers involved in the uranium
cycle. Collection of individual information on internal
uranium exposure as well as other risk factors is
underway, to allow for the investigation of uranium-
related risks.
INTRODUCTION
Ionising radiation is an established carcino-
gen1 and its effects on cancer risk are reason-
ably well understood and quantified, at least
at high doses (>100 mGy) and dose rates
(>5 mGy/h).2 By comparison, cancer risks
associated with internal exposures resulting
from the incorporation of radionuclides into
the body are less well quantified.3 This is a
major issue for radiation protection since
internal exposures are responsible for a large
portion of the population’s collective effect-
ive dose due to exposure to naturally occur-
ring radionuclides, such as radon, as well as
medical diagnostic and occupational sources
of internal exposures.1 In addition, there is
growing interest in health effects other than
cancer following exposure to low doses of
ionising radiation (eg, diseases of the circula-
tory system4), notably following internal
exposure.5
With the exception of studies on radon,
relatively few recent epidemiological studies
have directly quantified the health effects of
internal contamination in populations chron-
ically exposed to radionuclides.6–9 As a
result, the International Commission on
Radiological Protection, which elaborates
and periodically updates international radi-
ation protection recommendations, had to
estimate the radiation-related risks of internal
exposure to radionuclides, such as uranium,
by combining epidemiological evidence from
external exposure situations with that from
experimental studies on the biological effects
of internal emitters.10 It would be preferable
to have direct epidemiological evidence
regarding the effects of internal exposure to
such radionuclides. There is, therefore, the
need for further studies of populations
exposed to internal emitters, to help assess
Strengths and limitations of this study
▪ TRACY (TRAvailleurs du CYcle) is a new and rare
cohort of uranium fuel cycle workers.
▪ Almost 13 000 workers have been included from
1958 to 2006.
▪ Only 1% of workers were lost to follow-up.
▪ In France, individual causes of death are only
available since 1968.
▪ Further work is ongoing to allow for the detailed
investigation of uranium-related risk.
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the adequacy of current radiation protection standards
with respect to internal exposure.5
In addition to its radiological toxicity, uranium, as a
heavy metal, may exhibit chemical toxicity. This chem-
ical toxicity has been demonstrated on the kidney and
brain,11 and might possibly extend to other organs.
Therefore, even if models used to predict
radiation-induced health effects from uranium exposure
proved strictly adequate, additional data would be
needed to characterise the total (ie, radiological plus
chemical) health effects of uranium exposure in
humans. This further justifies the need to directly quan-
tify these effects in exposed populations.
Cohorts of workers involved in the uranium fuel cycle
are of interest to study the risks associated with internal
contamination by uranium because many workers have
been regularly monitored for internal exposure via bio-
assay analyses.5 However, few such cohorts have been set
up.12–18 A recent review concluded that, so far, studies
based on these cohorts have not provided reliable evi-
dence on the potential health risks associated with
uranium exposure, notably because of insufficient statis-
tical power.19 Pooling existing large cohorts of uranium
workers and setting up new ones is clearly needed to
improve the knowledge of the health effects of uranium
exposure.20
France has operated a complete nuclear fuel produc-
tion cycle since the 1960s. The French cohort of workers
employed in the nuclear fuel production cycle (TRACY,
TRAvailleurs du CYcle) was set up to assess the risk of
cancer and non-cancer mortality related to internal
exposure to uranium. Pilot studies were successfully con-
ducted in specific subsets of this large cohort.21 22 The
reconstitution of exposure data in the entire TRACY
cohort is underway.
The aim of the current investigation was to describe
mortality among the uranium workers in this new large
cohort, by comparison with the general population.
MATERIAL AND METHODS
Study design
TRACY is a retrospective cohort designed to study the
mortality of workers involved in the French uranium
fuel cycle. As will be detailed below, occupational data
were collected from 2009 to 2013 and cover a period
spanning from 1958 to 2006, whereas mortality data
cover a period spanning from 1968 to 2008.
Study population
The companies included in this study cover different
steps of the nuclear fuel production cycle in France
(figure 1): purification of concentrated natural
uranium, conversion to uranium hexafluoride, enrich-
ment by gaseous diffusion, fuel manufacturing and
other activities such as storage (depleted and repro-
cessed uranium), and decontamination (waste and efflu-
ents). Companies involved in uranium mining and
milling are not included, nor are companies that are
end users of the nuclear fuel (eg, those involved in elec-
tricity production). The companies included and their
respective main activities are presented in online supple-
mentary appendix table 1. TRACY is complementary to
the French uranium miners cohort23 and to the French
nuclear workers cohort, designed to study the associ-
ation between external chronic exposure to radiation
and mortality,24 whereas the main focus of TRACY is
internal contamination by uranium. The overlaps
between TRACY and the French cohorts of uranium
miners and nuclear workers include 158 and 5057 parti-
cipants, respectively.
Workers included in the cohort had to be employed
for at least 6 months as members of the permanent staff
of selected companies between 1958 and 2006. Personal
identifiers and work histories were provided by the
administrative departments of each company, either on
paper or electronic files. The files were computerised
whenever needed, validated and merged. Transfers from
one company to another were taken into account to
avoid duplicate counts and accurately reconstruct time
spent in the different companies included in the TRACY
cohort where workers were employed. The detailed char-
acterisation of workplaces and job titles is a long-term
task for this large cohort and is still underway.
The date of start of employment was defined as the
earliest one if several periods of employment were
recorded. The date of end of employment, whatever the
reason (retirement, resignation, dismissal, job transfer to
a company not included in the study), was identified
from the last recorded period of employment. For
workers still employed on 31 December 2006, the end of
employment was set to that date.
Follow-up, vital status and causes of death
For each worker, follow-up of vital status began on the
most recent date among the following: date of initial
employment plus 6 months, or 1 January 1968. The
lower bound of the follow-up period had to be set to that
date since the national registry that provides causes of
death information in France (CépiDC-Inserm) can
deliver no individual data before 1968. Among the
cohort members who began working before 1968, 53
had died or would have been lost to follow-up before
1968 and could not be included in the mortality study.
The date of end of follow-up was defined as the earliest
among the following: date of death, last information date
(for workers lost to follow-up) and 31 December 2008.
Workers’ vital status and the date of death for workers
who died were obtained from the National Vital Status
Registry (Répertoire National d’Identication des
Personnes Physiques) by file matching on name, sur-
names, gender, date and place of birth. To avoid errone-
ous linkages, only workers with one possible match with
the registry were considered as identified. Causes of
death coded according to the International Classification
of Diseases (ICD, V.8 for period 1968–1978, V.9 for
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1979–1999 and V.10 for period 2000–2008, see online
supplementary appendix table 2) and corresponding
labels were obtained by file matching on gender, date
and place of birth and date and place of death with the
French national mortality registry (CépiDC-Inserm).
In case of multiple matches, no causes could be obtained
for these workers.
Statistical analysis
Mortality rates were compared with those in the French
general population (also obtained from
CépiDC-Inserm) by computing standardised mortality
ratios (SMRs), therefore controlling for potential
confounders: sex, age (categorised as follows: 15–19,
20–24,…, 80–84, ≥85 years) and calendar period (cate-
gorised as follows: 1968–1972, 1973–1977,…, 1998–2002,
2003–2008) as classically performed for such analyses.25
Using the Poisson exact method, confidence intervals
(95% CIs) were calculated.26 This was performed for
specific causes of death (eg, cancer of specific organs or
tissues) or broader groupings of causes (eg, all cancers,
all circulatory diseases, cancer sites potentially associated
with smoking).27 Online supplementary appendix table
2 provides the definition and corresponding ICD codes
of all causes of death considered. For the primary ana-
lysis, SMRs were computed for men and women
grouped together. The ‘All causes’ group included
workers with non-identified causes of death. Results
were reported only for causes of death with at least five
cases observed across the whole cohort.
Supplementary analyses were conducted for broad
groupings of causes of death (all causes, cancers, dis-
eases of the circulatory system and respiratory diseases)
to examine the evolution of SMRs according to time
since hire (categorised as follows: <25, 25–39,
≥40 years), time since end of employment (categorised
as follows: <10, 10–19, ≥20 years), total duration of
employment (categorised as follows: <10, 10–24,
≥25 years) and attained age (categorised as follows: <50,
50–65, ≥66 years).28 Further analyses were conducted to
estimate SMRs among men and women separately. We
also conducted supplementary analyses according to
groupings of companies involved in the three main steps
of the uranium cycle (conversion, enrichment by
gaseous diffusion and manufacturing of oxide fuel), in
two ways. First, we considered workers involved in only
one grouping of companies covering a specific step
(therefore not allowing for overlap between population
subgroups, by excluding workers who got involved
during their careers in several groupings of companies
covering different steps) and second, considering
workers involved in at least one of these grouping of
companies (therefore allowing for overlap between the
population groupings analysed). For conversion, we con-
sidered workers employed by Comurhex (Malvési and
Pierrelatte plants). For enrichment, we considered a spe-
cific subcohort extract from the TRACY cohort with
Figure 1 Simplified diagram describing the French uranium fuel cycle.
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workers involved in both military and civil enrichment.29
Workers employed by FBFC-CERCA (Romans sur Isère
and Pierrelatte plants) constituted the oxide fuel manu-
facturing grouping.
All analyses were conducted using SAS software, V.9.2
(Cary, North Carolina, USA).
The protocol of this study was validated by the French
Data Protection Authority (CNIL), agreement number
DR-2012-611.
RESULTS
The inclusion process (summarised in online supple-
mentary appendix figure 1) started from a base of
21 143 potentially eligible workers. After removal of
duplicates (3063 tuples) and exclusion of workers who
did not match the eligibility criteria, 12 713 workers
were confirmed to be eligible and included in the study.
After further exclusion of one worker with identifiers
not sufficient to match with national files (place of birth
unknown) and of workers either dead or who would
have been lost to follow-up before 1968, the mortality
analysis was performed on 12 649 workers.
Workers excluded were permanent status workers who
cumulated less than 6 months of employment (N=641),
trainees (N=2561), short-term workers (N=2036) and
others special contracts (military service, scientific
advisor, N=129). Excluded workers cumulated an
average duration of work of 0.50 years. Contractors were
not mentioned in the employee personnel files and
therefore could not be considered.
The main characteristics of the cohort are presented
in table 1. Among the 12 649 workers included, 88%
were males. The cohort cumulated 342 258 person-years
of observation. The mean duration of follow-up was
27 years. The mean age at the end of the study was
60 years. The mean age at hire was 30 years and 49 years
at the end of employment. The mean duration of
employment was 19 years. At the end of the follow-up,
82% of workers were still alive, 17% were deceased and
1% were lost to follow-up. Underlying cause of death
was identified for 99% of the 2130 deaths recorded.
SMRs are presented in table 2 for the whole cohort.
A substantial mortality deficit was observed for all-cause
mortality compared to expectation based on French
national rates (SMR 0.65; 95% CI 0.62 to 0.68;
n=2130).
There was a substantial deficit in mortality for most
major categories of non-malignant diseases. All non-
cancer mortality was in 42% deficit (SMR 0.58; 95% CI
0.55 to 0.62, n=1012). There were substantial deficits in
deaths due to non-malignant respiratory diseases (SMR
0.51; 95% CI 0.41 to 0.63, n=88), circulatory diseases
(SMR 0.68; 95% CI 0.62 to 0.74, n=540), non-malignant
renal diseases (SMR 0.66; 95% CI 0.39 to 1.06, n=17)
and external causes of death including suicides and acci-
dents (SMR 0.54; 95% CI 0.46 to 0.62, n=186).
For deaths due to all malignant diseases grouped
together, there was also a deficit in the entire cohort
although less pronounced than for most non-malignant
categories of cause of death. Overall, cancer mortality
was in 24% deficit (SMR 0.76; 95% CI 0.71 to 0.81,
n=912). However, a twofold excess was observed for
pleural mesothelioma (SMR 2.04; 95% CI 1.19 to 3.27;
n=17) and non-significant excesses were observed for
other cancers: pancreas (SMR 1.05; 95% CI 0.79 to 1.38,
Table 1 Description of the TRACY cohort
Men Women All
Number Per cent Number Per cent Number Per cent
All workers 11 122 87.9 1527 12.1 12 649 100
Person-years 303 606 88.7 38 652 11.3 342 258 100
Vital status on 31 December 2008
Alive 8992 80.9 1386 90.8 10 378 82.1
Still employed 3937 35.4 620 40,6 4557 36.0
Deceased 2028 18.2 102 6.7 2130 16.8
With identified causes 2009 99.1 102 100 2111 16.7
Lost to follow-up 102 0.9 39 2.5 141 1.1
Median Mean Median Mean Median Mean
Year of birth 1943 1945 1949 1951 1944 1946
Age at death 67.8 66.4 60.9 62.2 67.5 66.2
Age at hiring 28.1 30.5 26.4 28.9 27.9 30.3
Age at end of employment (All) 53.8 49.8 47.5 45.5 53.1 49.3
Still employed 49.0 47.5 47.3 46.0 48.7 47.3
Not employed anymore 56.9 51.1 48.4 45.1 56.7 50.4
Duration of employment in years 19.9 19.4 14.3 16.6 19.3 19.0
Age at beginning of follow-up 31.2 33.2 29.0 31.1 31.0 32.9
Age at end of follow-up 61.1 60.5 56.3 56.5 60.6 60.0
Duration of follow-up in years 28.3 27.3 25.5 25.3 27.9 27.1
TRACY, TRAvailleurs du Cycle.
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Table 2 SMRs in the TRACY cohort (1968–2008)*
Cause of death
Observed number
of deaths SMR 95% CI
All causes 2130 0.65 (0.62–0.68)
Non-cancers diseases 1013 0.58 (0.55–0.62)
Diseases of the circulatory system 540 0.68 (0.62–0.74)
Hypertensive diseases 15 0.56 (0.31–0.93)
Ischaemic heart diseases 212 0.71 (0.62–0.81)
Cerebrovascular diseases 130 0.75 (0.63–0.90)
Other and unspecified disorders of the circulatory system 183 0.61 (0.52–0.71)
Respiratory diseases 88 0.51 (0.41–0.63)
Diseases of the digestive system (other than cirrhosis) 48 0.58 (0.43–0.77)
Diseases of the genitourinary system 23 0.70 (0.44–1.05)
Renal diseases 17 0.66 (0.39–1.06)
Other non-cancers diseases
Non-malignant tumours of central nervous system and sense organs 10 0.77 (0.37–1.42)
Endocrine, nutritional and metabolic diseases 47 0.67 (0.49–0.89)
Diseases of the blood and blood-forming organs 7 0.63 (0.25–1.30)
Cirrhosis, psychosis and other diseases due–alcohol 48 0.27 (0.20–0.35)
Non-tumoural diseases of central nervous system and sense organs 68 0.83 (0.64–1.05)
Diseases of the skin 5 1.14 (0.37–2.67)
Diseases of the musculoskeletal system and connective tissue 8 0.74 (0.32–1.46)
Other 121 0.43 (0.35–0.51)
All cancers 912 0.76 (0.71–0.81)
Smoking-related cancers 495 0.68 (0.62–0.75)
Mouth 13 0.46 (0.25–0.79)
Pharynx 28 0.57 (0.38–0.82)
Oesophagus 33 0.52 (0.36–0.73)
Stomach 29 0.64 (0.43–0.92)
Liver 31 0.65 (0.44–0.92)
Pancreas 53 1.05 (0.79–1.38)
Nasal cavity, sinus and middle ear 5 0.24 (0.08–0.57)
Larynx 20 0.49 (0.30–0.75)
Lung 217 0.73 (0.64–0.83)
Bladder 26 0.69 (0.45–1.01)
Kidney 24 0.84 (0.54–1.24)
Non-smoking-related cancers 358 0.87 (0.79–0.97)
Colon 60 0.78 (0.60–1.01)
Rectum 26 0.87 (0.57–1.28)
Gallbladder and bile ducts 7 0.98 (0.39–2.01)
Pleura 17 2.04 (1.19–3.27)
Melanoma 15 1.60 (0.90–2.64)
Breast 20 1.32 (0.81–2.04)
Prostate 71 0.94 (0.74–1.19)
Brain and central nervous system 32 1.36 (0.93–1.91)
Other non-smoking-related cancers 106 0.69 (0.57–0.84)
Haematological and lymphatic malignancies 74 0.96 (0.75–1.20)
Leukaemia 33 1.00 (0.69–1.40)
Lymphocytic leukaemia 12 1.38 (0.71–2.42)
Chronic lymphocytic leukaemia (CLL) 8 1.28 (0.55–2.52)
Myeloid leukaemia 15 1.06 (0.59–1.74)
Acute myeloid leukaemia 10 1.22 (0.58–2.24)
Other leukaemia 6 0.59 (0.22–1.28)
Leukaemia without CLL 25 0.93 (0.60–1.38)
Multiple myeloma 18 1.29 (0.77–2.05)
Non-Hodgkin’s lymphoma 23 0.86 (0.55–1.30)
External causes 186 0.54 (0.46–0.62)
Suicides 77 0.66 (0.52–0.82)
Accidents 98 0.47 (0.39–0.58)
Other external causes 11 0.49 (0.24–0.87)
*For causes of deaths with at least 5 cases observed.
SMRs, standardised mortality ratios; TRACY, TRAvailleurs du CYcle.
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n=53), skin melanoma (SMR 1.60; 95% CI 0.90 to 2.64,
n=15), breast (all observed cases being among women,
see online supplementary appendix table 3; SMR 1.53;
95% CI 0.94 to 2.37; n=20), brain and central nervous
system (SMR 1.36; 95% CI 0.93 to 1.91, n=32), lympho-
cytic (SMR 1.38; 95% CI 0.71 to 2.42, n=12) and
myeloid (SMR 1.06; 95% CI 0.59 to 1.74, n=15) leukae-
mia and multiple myeloma (SMR 1.29; 95% CI 0.77 to
2.05, n=18). In contrast, there was a substantial deficit in
deaths due to smoking-related cancers (SMR 0.68; 95%
CI 0.62 to 0.75, n=495).
SMRs for cancer diseases tended to increase with time
since hire, time since end of employment and attained
age (table 3). Twenty years after the end of employment,
the risk of cancer mortality is not significantly different
from that in the general population, whereas it remains
Table 3 SMRs and 95% CI in the TRACY cohort (1968–2008), by time since hire, time since end of employment, duration
of employment and age reached, for broad groupings of causes of death
Time since hire
Less than 25 years 25–39 years 40 years or more
Cause of
death
Observed
Number of
deaths SMR 95% CI
Observed
Number of
deaths SMR 95% CI
Observed
Number of
deaths SMR 95% CI
All causes 633 0.54 (0.50 to 0.58) 967 0.70 (0.66 to 0.75) 530 0.73 (0.66 to 0.79)
All cancers 242 0.64 (0.57 to 0.73) 457 0.81 (0.74 to 0.89) 213 0.82 (0.71 to 0.93)
Circulatory
diseases
160 0.67 (0.57 to 0.79) 235 0.66 (0.58 to 0.75) 145 0.71 (0.60 to 0.83)
Respiratory
diseases
14 0.33 (0.18 to 0.55) 48 0.61 (0.45 to 0.81) 26 0.50 (0.33 to 0.73)
Time since end of employment
Less than 10 years 10–19 years 20 years or more
Cause of
death
Observed
Number of
deaths SMR 95% CI
Observed
Number of
deaths SMR 95% CI
Observed
Number of
deaths SMR 95% CI
All causes 945 0.56 (0.52 to 0.59) 591 0.74 (0.68 to 0.80) 594 0.75 (0.70 to 0.82)
All cancers 430 0.68 (0.62 to 0.75) 243 0.81 (0.71 to 0.92) 239 0.89 (0.79 to 1.02)
Circulatory
diseases
217 0.62 (0.54 to 0.71) 162 0.72 (0.61 to 0.84) 161 0.72 (0.61 to 0.84)
Respiratory
diseases
16 0.25 (0.14 to 0.41) 39 0.75 (0.53 to 1.02) 33 0.58 (0.40 to 0.81)
Duration of employment
Less than 10 years 10–24 years 25 years or more
Cause of
death
Observed
Number of
deaths SMR 95% CI
Observed
Number of
deaths SMR 95% CI
Observed
Number of
deaths SMR 95% CI
All causes 575 0.66 (0.61 to 0.71) 1073 0.67 (0.63 to 0.71) 482 0.60 (0.55 to 0.66)
All cancers 243 0.82 (0.72 to 0.93) 426 0.78 (0.70 to 0.85) 243 0.69 (0.61 to 0.78)
Circulatory
diseases
126 0.66 (0.55 to 0.79) 314 0.73 (0.65 to 0.82) 100 0.56 (0.45 to 0.68)
Respiratory
diseases
25 0.62 (0.40 to 0.92) 48 0.50 (0.37 to 0.67) 15 0.40 (0.22 to 0.66)
Attained age
Less than 50 years old 50–65 years old 66 years old or more
Cause of
death
Observed
Number of
deaths SMR 95% CI
Observed
Number of
deaths SMR 95% CI
Observed
Number of
deaths SMR 95% CI
All causes 269 0.50 (0.44 to 0.56) 662 0.56 (0.52 to 0.61) 1199 0.77 (0.72 to 0.81)
All cancers 78 0.60 (0.48 to 0.75) 358 0.70 (0.63 to 0.77) 476 0.86 (0.78 to 0.94)
Circulatory
diseases
52 0.67 (0.50 to 0.87) 147 0.59 (0.50 to 0.69) 341 0.73 (0.65 to 0.81)
Respiratory
diseases
5 0.38 (0.12 to 0.88) 13 0.29 (0.16 to 0.50) 70 0.61 (0.48 to 0.77)
SMRs, standardised mortality ratios; TRACY, TRAvailleurs du CYcle.
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significantly lower for circulatory and respiratory dis-
eases. No clear trend was observed according to the dur-
ation of employment for mortality from all causes and
from circulatory diseases. However, there was evidence
of a decreasing trend along with duration of employ-
ment for mortality from cancer and respiratory diseases.
For all broad groupings of causes of death, the lowest
SMRs were observed in workers with the longest dur-
ation of employment (table 3).
Significant deficits in all-cause and non-cancer mortal-
ity were observed for both genders (see online supple-
mentary appendix tables 3 and 4). In women,
non-significant excesses of cancer mortality were
observed. However, CIs were very wide due to the lower
number of women (and, therefore, of deaths observed
in these women) in the cohort (see online supplemen-
tary appendix table 3). In men, a significant deficit in
mortality from all cancers was also observed and results
were overall comparable to those in the entire cohort
(see online supplementary appendix table 4).
For all groupings of causes of death considered, we
observed no difference in mortality patterns according to
groupings of companies involved in the main three steps
of the cycle, regardless of the way the groupings were
defined (see online supplementary appendix table 5).
DISCUSSION
This is the first mortality study conducted in this new
cohort of uranium cycle workers, which is one of the
largest of its kind. A healthy worker effect (HWE) is
observed. It is especially strong for major groups of non-
cancer diseases, including circulatory and non-cancer
respiratory diseases. For all cancers grouped together, a
healthy worker effect is also observed overall, but is less
marked than for non-cancer diseases. No deficit in
cancer mortality is observed in workers 20 years or older
after the end of employment, or in women. A significant
excess of malignant pleural mesothelioma is observed
and non-significant excesses are observed for a few
other specific cancer sites.
Mortality profile
The HWE is often observed in occupational cohorts,
including nuclear worker cohorts.24 25 28 It partly results
from the selection of healthier people at hiring
(referred to as the ‘healthy hire effect’,28 which tends to
shrink with time since hire) and from other selection
effects making the healthiest individuals more likely to
be retained in the workforce than individuals with
poorer health (referred to as the ‘healthy survivor
effect’28 and reflected by the fact that workers with the
longest duration of employment exhibit the lowest
SMRs). The regular health surveillance provided by
occupational medicine services as well as other factors
such as work-related physical activity are also suspected
to contribute to the healthy survivor effect. As time since
the end of employment goes by, the mortality profile of
workers tends to reach that of the general population.
These patterns were observed in the TRACY cohort, in
agreement with previous literature.24 25 28 Methods have
been proposed to calculate adjusted SMRs as a comple-
ment to the traditional SMR which may facilitate inter-
pretation of findings in spite of comparability issues due
to the HWE; a recent example of such an approach
draws on methods developed for the use of negative
control outcomes for bias reduction.30 Such methods
have not been applied in the current paper, however,
since it is difficult to define a relevant negative control
outcome for a population of workers exposed to
uranium. In spite of the aforementioned limitations
resulting from the HWE, comparisons of mortality pro-
files of occupational cohorts with those of general popu-
lations have been considered to be a useful approach
and, therefore, have been widely used in occupational
epidemiology.18 25 31 32
Importantly, the observed HWE does not mean that
no case attributable to uranium or to other sources of
radiation occurred in the TRACY cohort. The present
analysis provides a simple but informative picture of the
general level of risk in this cohort of workers of the
uranium fuel cycle, through a comparison with the
general population. The risk in the cohort is not only
influenced by uranium and other radiation exposures
but also by the levels of exposure to other risk factors.
For instance, the SMR for the grouping of cancer sites
that may be caused by smoking27 is low in the TRACY
cohort. This suggests a lower level of exposure to
smoking in this cohort than in the general population.
Conversely, we observed an excess of pleural meso-
thelioma. We acknowledge that the diagnosis and ascer-
tainment of mesothelioma on death certificates has
been problematic until at least the early 1990s.33 This
limitation applied both to the TRACY cohort and to the
comparison group, the French general population.34
The ascertainment of mesothelioma improved with the
introduction of ICD10,35 which was used since year 2000
for French death certificates. Excesses of pleural meso-
thelioma were also reported in most other nuclear
worker cohort studies.36 An excess risk was also observed
in the French cohort of nuclear workers, designed to
study the effects of external radiation exposure (based
on 36 deaths),37 but it has to be noted that these two
results are not independent, due to partial overlap of
the two cohorts, concerning workers from AREVA NC
and CEA Pierrelatte plant (10 deaths in common,
among 5057 workers included in both cohorts).
Evidence for an association between exposure to ionis-
ing radiation and pleural mesothelioma is weak,
however,36 and, to the best of our knowledge, no associ-
ation between uranium exposure and mesothelioma has
ever been reported. By contrast, asbestos exposure is a
strong risk factor for this disease, and has been known
to occur in companies included in TRACY,38 as well as
in other companies in which some workers were
employed before joining the nuclear fuel industry. This
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might contribute to the excess of malignant pleural
mesothelioma observed in this cohort.
Non-significant excesses were observed for a few
cancer sites in TRACY. For pancreas cancer, non-
significantly positive SMRs were also observed in several
other cohorts of uranium workers (including uranium
millers)14 17 39 40 but not in all15 18 31 32 41 (see online
supplementary appendix table 6).
For all leukaemias grouped together, patterns are not
consistent across cohorts either. A proper comparison by
leukaemia subtype is hampered by the inhomogeneous
sets of subtypes for which results were reported in avail-
able studies. However, non-significant excesses of mul-
tiple myeloma17 39 42 or myeloma32 were reported in
most cohorts that evaluated this outcome (see online
supplementary appendix table 6).
Non-significant excesses of cancers of the brain and
central nervous system were reported in most cohorts of
uranium workers.14 32 39–41 43 Although no single study
detected a significant excess of brain cancer, the consist-
ent pattern of non-significant excesses across cohorts for
this outcome deserves further investigation (see online
supplementary appendix table 6). Animal studies have
shown that the brain is a target organ for uranium
effects,44–46 although, to the best of our knowledge, no
animal study has specifically focused on brain or central
nervous system cancers.
Only one other cohort of uranium fuel cycle workers
reported a non-significant excess of skin cancer so far.14
Only three studies reported non-significant excesses of
breast cancer14 15 18 and in two of them, the excess was
only observed in women monitored for internal
contamination.15 18
Strengths and limitations
The TRACY cohort has major strengths, such as its large
size and excellent quality of follow-up. It is one of the
rare cohorts of uranium fuel cycle workers in the world.
However, the present study also has some limitations. No
individual data on causes of death were available before
1968 due to the late introduction of the French mortal-
ity registry. This limitation applies to all epidemiological
studies in France. Uranium-related activities began as
early as 1959 in some companies included in TRACY.
However, the gap in temporal overlap before year 1968
could not hamper the detection of potential excess of
diseases occurring after a long latency time following
occupational exposure (eg, solid cancers are usually con-
sidered to occur after 10 or more years following radi-
ation exposure). Similarly, the fact that occupational
data have not been collected after year 2006 so far,
although the mortality analysis covered the period 1968–
2008, is unlikely to generate a substantial impact on the
analysis of diseases with long latency times. However, the
possible impact of the aforementioned lack of temporal
overlap is less clear for diseases with shorter latency
times, such as leukaemia. In addition, although the use
of mortality data is very informative, it does not allow
capturing the full range of possible health effects of
uranium exposure, for instance, cognitive, reproductive
effects or kidney damage.11 More generally, it does not
adequately capture the incidence of diseases that are
rarely fatal.
The criteria for inclusion into the TRACY cohort guar-
antees that all permanent staff workers potentially
exposed to uranium as part of the upstream steps of the
French nuclear fuel cycle (except miners and millers)
are included. However, it is clear that some workers not
exposed to uranium are also included in the cohort.
Having these workers in the cohort will be useful to con-
stitute an internal reference group, when associations
between uranium exposure and mortality will be
studied. However, further work is still needed (especially
a detailed reconstruction of bioassay record histories)
before being able to separate all workers exposed from
those non-exposed to uranium in the entire TRACY
cohort. Complex changes in industrial processes com-
bined with changes in individual job histories make it a
long-term task.
However, as a preliminary approach, we explored the
hypothesis of different health effects according to differ-
ent parts of the uranium cycle, by conducting a first ana-
lysis by groupings of companies involved in the three
main steps of the uranium cycle (conversion, enrich-
ment and fuel manufacturing). We failed to demonstrate
potential differences, possibly because of the lack of stat-
istical power and inclusion of non-exposed workers in
each group.
Perspectives
The reconstruction of the multiple exposures of the
workers in the TRACY cohort represents a necessary
effort to assess risks according to different levels of
exposure to uranium, while taking into account other
sources of radiation (external exposure to X-ray and
gamma rays, and internal contamination with radionu-
clides such as, for instance, uranium decay products,
plutonium and tritium) and other potential risk factors,
including carcinogenic, mutagenic or toxic to reproduc-
tion chemicals, heat, noise and shift work. Uranium
exposure is being reconstructed by a dual approach
combining individual monitoring data47 and specific
job-exposure matrices.38 Job exposure matrices allow
estimating exposures not covered by any individual mon-
itoring and document uranium compounds present at
each job. This detailed exposure reconstruction will
allow us to distinguish more finely the different steps of
the uranium fuel cycle and therefore better characterise
the physicochemical characteristics of the different
uranium compounds (in term of solubility and isotopy)
to which workers were exposed.
The calculation of uranium concentrations in the
target organs of uranium (eg, lungs, kidneys, bones and
brain, among others) but also of resulting absorbed radi-
ation doses to these same organs, will help in disentan-
gling chemical from radiation effects of uranium
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exposure. This specific investigation will be possible
since separate populations of workers have been
exposed to uranium of different isotopic compositions,
which show contrasted specific activity (eg, 0.33 μCi/g
for depleted uranium, 0.68 μCi/g for natural uranium
and up to 50 μCi/g for enriched uranium). Since
depleted uranium has a very low specific activity, an esti-
mate of the relationship between depleted uranium con-
centrations in organs and health risks will almost purely
assess the potential chemical toxicity of uranium. Beside
this, workers exposed to a same level of uranium con-
centration in organs will receive different internal radi-
ation dose from this nuclide, depending on whether
they were exposed to depleted, natural or enriched
uranium (again, because of their varying specific activ-
ities). Comparing risks in workers exposed to uranium
of different isotopic compositions will therefore provide
an opportunity to isolate and quantify the radiological
component of uranium toxicity. Last, information on
risk factors such as tobacco smoking and various clinical
parameters (body mass index, blood pressure, lipid
profile, etc) is being collected from the occupational
health services,48 which will allow controlling for their
potential confounding effects in future analyses.
The TRACY cohort is still young, with an average age
of 60 years, and only 17% of workers were deceased at
the end of follow-up. The statistical power available to
study rare or specific diseases (eg, specific cancer sites)
will remain limited in this cohort as well as in other
cohorts of nuclear fuel cycle workers, unless large
excesses actually occur (as was observed in TRACY, for
pleural mesothelioma). Extended follow-up and pooled
analyses of these cohorts, including TRACY, are needed
to produce more statistically precise estimates, which will
allow drawing more robust conclusions on possible
excess for these diseases and their association with
uranium exposure. A pooling of TRACY with other
cohorts of uranium workers and miners in Europe is
planned, according to harmonised methodologies
defined as part of the European project CURE.20 In the
future, this approach could be extended to cohorts
outside Europe.
CONCLUSION
This first mortality study of the TRACY cohort of French
uranium cycle workers has shown a substantial mortality
deficit for all broad groupings of causes of death and
most of the pathologies studied. However, a significant
excess of malignant pleural mesothelioma was also
observed and non-significant excesses were observed for
a few specific cancer sites. To go further in the investiga-
tion of uranium-related risks in this new cohort, collec-
tion of individual information on internal uranium
exposure as well as other risk factors is underway.
Finally, through the pooling of TRACY with other
cohorts of uranium workers, the TRACY cohort will help
to improve the knowledge of the health effects of
uranium exposure and more generally of internal con-
taminations by radionuclides, in support of radiation
protection research and practice.
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